Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer treatment in hours, not weeks: new study tests One-Stop radiotherapy

NCT ID NCT06236516

First seen May 07, 2026 · Last updated Jun 22, 2026 · Updated 8 times

Summary

This study tested a new way to deliver a single, high-dose radiation treatment (SBRT) for small lung tumors. Normally, this process takes two to three weeks and multiple hospital visits. The new 'ONE STOP' approach aims to do everything—from planning to treatment—in just a few hours, using advanced imaging and AI. Ten patients with early-stage lung cancer or limited lung metastases took part to see if this faster workflow was feasible and safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radiation therapy (SBRT)

What this could lead to

If successful, this could make lung cancer radiotherapy much faster and more accessible, reducing the need for multiple hospital visits.

What could go wrong

This is a very small feasibility study with only 10 participants. It tests a new workflow, not a new treatment, so benefits are about convenience, not cure. Technical failures or poor image quality could limit its use.

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.